Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
(Continued)<br />
justed<br />
Vivax efficacy: P.<br />
vivax parasitaemia<br />
by Day 42<br />
Transmission<br />
potential: Gametocyte<br />
carriage<br />
Harms: Serious adverse<br />
events (including<br />
deaths)<br />
Harms: Early vomiting<br />
667 per 1000 700 per 1000<br />
(507 to 954)<br />
RR 1.05<br />
(0.76 to 1.43)<br />
72<br />
(1)<br />
- - - 158<br />
(1)<br />
- - - 197<br />
(1)<br />
⊕<br />
very low 2,3,7,8<br />
- 9<br />
⊕<br />
very low 10,11<br />
- - - - Not reported<br />
*<strong>The</strong> assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control<br />
groups with the event divided by the total number of patients in control groups. <strong>The</strong> corresponding risk (and its 95% confidence<br />
interval) is <strong>based</strong> on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br />
CI: confidence interval; RR: risk ratio<br />
GRADE Working Group grades of evidence<br />
High quality: Further research is very unlikely to change our confidence in the estimate of effect.<br />
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change<br />
the estimate.<br />
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to<br />
change the estimate.<br />
Very low quality: We are very uncertain about the estimate.<br />
Footnotes<br />
1 Please note that due to its longer half-life, PCR adjusted treatment failure with AL6 may be underestimated at this time point.<br />
2 Karunajeewa 2007 PNG.<br />
3 Serious limitations: Allocation concealment was assessed as ’high risk of bias’ in this trial. Only microscopists were blinded to treatment<br />
allocation.<br />
4 Very serious indirectness: Data are only available from one country (Papua New Guinea). One other trial from Sudan with high risk<br />
of bias (Mukhtar 2005 SDN) reports data <strong>for</strong> day 28 and did not find a difference.<br />
5 No serious imprecision: <strong>The</strong> 95% CI includes appreciable and non-appreciable benefit with AL6 over AS+SP but does not cross the<br />
line of no effect.<br />
6 Very serious imprecision: <strong>The</strong> 95% CI is very wide including appreciable benefit and harm with each drug over the other.<br />
7 Serious indirectness: Data are only available from one country (Papua New Guinea). This outcome is <strong>for</strong> participants with P. vivax ±<br />
P. falciparum at baseline.<br />
8 Serious imprecision: <strong>The</strong> 95% CI includes appreciable benefit with AS+SP and crosses the line of no effect.<br />
9 Karunajeewa 2007 PNG reports no differences in gametocyte carriage between the two groups during follow up (figures not given).<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
257